Avantor, Inc. (NYSE:AVTR) Receives $26.15 Consensus Target Price from Analysts

Avantor, Inc. (NYSE:AVTR) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $25.92.

Several research firms recently weighed in on AVTR. Royal Bank of Canada decreased their target price on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating for the company in a research note on Monday, February 10th. Wells Fargo & Company dropped their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. UBS Group reissued a “neutral” rating and set a $25.00 price target (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Robert W. Baird dropped their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Stifel Nicolaus reduced their target price on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, February 10th.

Institutional Trading of Avantor

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB boosted its position in shares of Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after buying an additional 625 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after acquiring an additional 830 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after buying an additional 835 shares in the last quarter. Global Retirement Partners LLC raised its holdings in Avantor by 76.7% during the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after acquiring an additional 1,067 shares during the period. Finally, UMB Bank n.a. lifted its position in shares of Avantor by 56.3% during the fourth quarter. UMB Bank n.a. now owns 2,981 shares of the company’s stock worth $63,000 after acquiring an additional 1,074 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Avantor Stock Down 3.2 %

NYSE:AVTR opened at $17.31 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. Avantor has a 12-month low of $17.19 and a 12-month high of $28.00. The stock’s fifty day simple moving average is $21.36 and its 200-day simple moving average is $23.14. The firm has a market capitalization of $11.78 billion, a P/E ratio of 37.62, a P/E/G ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same period in the previous year, the firm posted $0.22 earnings per share. Equities research analysts expect that Avantor will post 0.98 earnings per share for the current year.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.